Evidence map›Paper›PMID 31366914›Full record

Trial reportBlood cancer journal2019

A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma.

Andrew Spencer, Patricia Walker, Parisa Asvadi, Douglas H Campbell, Kate Reed, Ben R Herbert, Edmond J Breen, Michael C Copeman, Rosanne D Dunn

Abstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrew SpencerAlfred Health-Monash University, Melbourne, VIC, Australia. aspencer@netspace.net.au.
Patricia WalkerAlfred Health-Monash University, Melbourne, VIC, Australia.
Parisa AsvadiAurobindo Pharma Ltd, Hyderabad, AP, India.
Douglas H CampbellMinomic International Ltd, Sydney, NSW, Australia.
Kate ReedAlfred Health-Monash University, Melbourne, VIC, Australia.
Ben R HerbertKolling Institute, Northern Sydney Local Health District, Sydney Medical School Northern, University of Sydney, St Leonards, NSW, Australia.
Edmond J BreenAustralian Proteome Analysis Facility, Macquarie University, Sydney, NSW, Australia.
Michael C Copeman45 Baringa Road, Northbridge, NSW, Australia.
Rosanne D DunnHaemaLogiX Pty Ltd, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalDose-Response Relationship, DrugHumansImmunoglobulin kappa-ChainsMiddle AgedMultiple MyelomaPrognosisTissue DistributionAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalImmunoglobulin kappa-ChainsMDX-1097

Identifiers

PMID31366914
PMCPMC6668455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.